Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 4:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 2,869 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: HSCT Clear all
Not yet recruiting Not applicable Interventional

Meaning-Centered Psychotherapy for Addressing Existential Distress of Patient/Caregiver Dyads Following Hematopoietic Stem Cell Transplantation: Feasibility and Acceptability

NCT07595146
View directory record Official record
Conditions
Hematopoietic Stem Cell Transplant
Interventions
Meaning-Centered Psychotherapy, Usual Care
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 22, 2026, 4:03 AM EDT
Terminated Phase 2 Interventional Results available

Stem Cell Transplantation for Metastatic Solid Tumors

NCT00001880
View directory record Official record
Conditions
Neoplasm Metastasis
Interventions
methotrexate, Cyclosporin
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
10 Years to 80 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 10, 2021 · Synced Oct 22, 2026, 4:03 AM EDT
Active, not recruiting Not applicable Interventional

Unrelated And Partially Matched Related Donor PSCT w/ T Cell Receptor (TCR) αβ Depletion for Patients With BMF

NCT03047746
View directory record Official record
Conditions
Acquired Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria, Inherited Bone Marrow Failure Syndromes
Interventions
CliniMACs
Device
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Up to 25 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2029
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 22, 2026, 4:03 AM EDT
Recruiting Not applicable Interventional

CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT

NCT03810196
View directory record Official record
Conditions
Acute Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Acute Lymphoblastic Leukemia, Mixed Lineage Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma, Juvenile Myelomonocytic Leukemia
Interventions
CliniMACS Cell Processing System for TCRαβ + T Cell and CD45RA Depleted Peripheral Stem Cell Addback
Device
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Up to 25 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 22, 2026, 4:03 AM EDT
Withdrawn Phase 2 Interventional

Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation

NCT06348147
View directory record Official record
Conditions
Newly Diagnosed Multiple Myeloma, Multiple Myeloma, Autologous Stem Cell Transplantation
Interventions
Daratumumab, Lenalidomide, Bortezomib, Dexamethasone
Biological · Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 22, 2026, 4:03 AM EDT
Completed Phase 2 Interventional Results available

1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation

NCT03133221
View directory record Official record
Conditions
Non Hodgkin Lymphoma, Follicular Lymphoma, Indolent Lymphoma, B-cell Lymphoma, Transformed Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma
Interventions
Zydelig
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
3
States / cities
Miami, Florida • Baltimore, Maryland • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 27, 2025 · Synced Oct 22, 2026, 4:03 AM EDT
Completed Phase 1 Interventional

Bone Marrow and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

NCT00004232
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous/Nonmalignant Condition
Interventions
filgrastim, cyclosporine, methylprednisolone, prednisone, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Northwestern University
Other
Eligibility
10 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 1, 2012 · Synced Oct 22, 2026, 4:03 AM EDT
Completed Not applicable Interventional

Positive Psychology Intervention to Improve Quality of Life in Stem Cell Transplant Survivors and Their Caregivers

NCT03525106
View directory record Official record
Conditions
Hematopoietic Cell Transplantation Recipient
Interventions
Booklet, Exercise Intervention, Quality-of-Life Assessment, Survey Administration, Telephone-Based Intervention
Behavioral · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 4, 2020 · Synced Oct 22, 2026, 4:03 AM EDT
Completed Phase 2 Interventional

Gemcitabine and Vinorelbine in Treating Young Patients With Recurrent or Refractory Hodgkin's Lymphoma

NCT00070304
View directory record Official record
Conditions
Lymphoma
Interventions
filgrastim, gemcitabine hydrochloride, vinorelbine tartrate
Biological · Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 30 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
108
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 93 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2013 · Synced Oct 22, 2026, 4:03 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

ACT to Reduce Morbidity and Mortality in Hematopoietic Stem Cell Transplant Patients

NCT07516314
View directory record Official record
Conditions
Stem Cell Transplant Patients
Interventions
ACTivate sessions
Behavioral
Lead sponsor
Anthony Sung, MD
Other
Eligibility
18 Years to 80 Years
Enrollment
476 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2031
U.S. locations
2
States / cities
Kansas City, Kansas • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 22, 2026, 4:03 AM EDT
Completed Phase 1 Interventional

Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers

NCT01254578
View directory record Official record
Conditions
Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1, Adult Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A, Adult Acute Promyelocytic Leukemia With PML-RARA, Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-Cell Lymphoma, Alkylating Agent-Related Acute Myeloid Leukemia, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-Cell Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Hepatosplenic T-Cell Lymphoma, Intraocular Lymphoma, Lymphomatous Involvement of Non-Cutaneous Extranodal Site, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Nodal Marginal Zone Lymphoma, Post-Transplant Lymphoproliferative Disorder, Primary Cutaneous B-Cell Non-Hodgkin Lymphoma, Prolymphocytic Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Immunoblastic Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-Cell Leukemia/Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides and Sezary Syndrome, Recurrent Non-Hodgkin Lymphoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Richter Syndrome, Small Intestinal Lymphoma, Splenic Marginal Zone Lymphoma, T-Cell Large Granular Lymphocyte Leukemia, Testicular Lymphoma, Waldenstrom Macroglobulinemia
Interventions
Laboratory Biomarker Analysis, Lenalidomide, Pharmacological Study
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 25, 2017 · Synced Oct 22, 2026, 4:03 AM EDT
Active, not recruiting Phase 1 Interventional

Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN

NCT03613532
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML), MDS/Myeloproliferative Neoplasm-unclassifiable (MDS/MPN-unclassifiable), Hematopoietic Stem Cell Transplant
Interventions
Venetoclax, Fludarabine, Busulfan, Azacitidine, Decitabine/cedazuridine
Drug
Lead sponsor
Jacqueline Garcia, MD
Other
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 22, 2026, 4:03 AM EDT
Recruiting Phase 1 Interventional

PTCY Plus uhCG/EGF for Graft Versus Host Disease Prophylaxis

NCT04886726
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
uhCG/EGF
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 22, 2026, 4:03 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Allo Transplant Followed by Lenalidomide and Sirolimus Maintenance in High-Risk Multiple Myeloma (MM)

NCT01303965
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Sirolimus, Tacrolimus, Lenalidomide
Drug
Lead sponsor
Sherif S. Farag
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Oct 22, 2026, 4:03 AM EDT
Completed No phase listed Observational

Response to SARS-CoV-2 Vaccine in Stem Cell Transplant and Cellular Therapy Patients

NCT04723706
View directory record Official record
Conditions
Hematologic Disorders and Bone Marrow Failure, Hematopoietic Stem Cell Transplantation (HSCT) or Cellular Therapy (CART)
Interventions
COVID-19 serology IgG
Diagnostic Test
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 80 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Oct 22, 2026, 4:03 AM EDT
Completed Phase 3 Interventional Results available

Study Comparing Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients

NCT02851407
View directory record Official record
Conditions
Veno-occlusive Disease
Interventions
Defibrotide, Best Supportive Care
Drug · Other
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
1 Month and older
Enrollment
372 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
37
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Oct 22, 2026, 4:03 AM EDT
Terminated Phase 3 Interventional

Study Comparing STR (Skeletal Targeted Radiotherapy) Plus Melphalan to Melphalan Alone, With Stem Cell Transplant in Multiple Myeloma

NCT00083564
View directory record Official record
Conditions
Multiple Myeloma
Interventions
STR(TM) (Skeletal Targeted Radiotherapy, Holmium-166-DOTMP)
Drug
Lead sponsor
Poniard Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
20
States / cities
Birmingham, Alabama • Orange, California • Denver, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2009 · Synced Oct 22, 2026, 4:03 AM EDT
Completed No phase listed Observational

Pulmonary Disease in Patients Undergoing Hematopoietic Stem Cell Transplantation

NCT01420172
View directory record Official record
Conditions
Post Hematopoietic Stem Cell Transplantation
Interventions
Data Collection
Other
Lead sponsor
Karen Wood
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Oct 22, 2026, 4:03 AM EDT
Completed No phase listed Observational Results available

Bridging Pediatric and Adult Biomarkers in Graft-Versus-Host Disease

NCT02194439
View directory record Official record
Conditions
Graft-Versus-Host Disease
Interventions
Not listed
Lead sponsor
Indiana University
Other
Eligibility
Not listed
Enrollment
415 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 26, 2021 · Synced Oct 22, 2026, 4:03 AM EDT
Completed Phase 1 Interventional Results available

Probiotic Use in Children Undergoing Hematopoietic Stem Cell Transplantation (HSCT)

NCT01010867
View directory record Official record
Conditions
Hematopoietic Organs; Disorder
Interventions
Lactobacillus plantarum strains 299 and 299v
Drug
Lead sponsor
Columbia University
Other
Eligibility
2 Years to 17 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
3
States / cities
Jacksonville, Florida • St. Petersburg, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 13, 2017 · Synced Oct 22, 2026, 4:03 AM EDT
Active, not recruiting Phase 2 Interventional

Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis

NCT04384692
View directory record Official record
Conditions
Primary Myelofibrosis, Secondary Myelofibrosis
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Busulfan, Cyclophosphamide, Fludarabine, Melphalan, Methotrexate, Mycophenolate Mofetil, Ruxolitinib, Tacrolimus, Total-Body Irradiation, Computed Tomography, Echocardiography, Bone Marrow Aspiration and Biopsy, Magnetic Resonance Imaging, Ultrasound Imaging
Procedure · Drug · Radiation
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 22, 2026, 4:03 AM EDT
Completed Phase 2 Interventional

Sirolimus & Mycophenolate Mofetil as GVHD Prophylaxis in Myeloablative, Matched Related Donor HCT

NCT00350181
View directory record Official record
Conditions
Leukemia, Lymphoma, Non-Hodgkin, Hematologic Diseases, Acute GVHD
Interventions
Sirolimus, MMF, BCNU, VP-16, CY, FTBI, BU
Drug
Lead sponsor
Stanford University
Other
Eligibility
2 Years to 60 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 23, 2021 · Synced Oct 22, 2026, 4:03 AM EDT
Active, not recruiting Phase 1 Interventional

T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia

NCT03531736
View directory record Official record
Conditions
Myeloid Diseases
Interventions
Antithymocyte globulin (Rabbit), fludarabine, total body irradiation, cyclophosphamide, Rituxan, Allogeneic Hematopoietic Stem Cell Transplantation
Drug · Radiation · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
2
States / cities
Middletown, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 22, 2026, 4:03 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant

NCT02506933
View directory record Official record
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission, Chronic Lymphocytic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Cytomegaloviral Infection, Hodgkin Lymphoma, Lymphadenopathy, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, Myelofibrosis, Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma
Interventions
Laboratory Biomarker Analysis, Multi-peptide CMV-Modified Vaccinia Ankara Vaccine, Placebo
Other · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
3
States / cities
Duarte, California • Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 22, 2026, 4:03 AM EDT